Sunday 18 October 2026
Export EVAX’s income statement to Excel — free account
Evaxion A/S - Sponsored ADR
EVAX Healthcare Biotechnology
Evaxion A/S - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, up 125.1% from fiscal 2024. In the quarter to June 2026, revenue grew 14,590.2%, EPS fell 72.4% and free cash flow fell 56.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.83
0.03
+1.07%
Follow EVAX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
2.24 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(3.10) | — | — | — | |
P/B ratio |
1.44 | — | — | — | |
Price to Tangible BV |
1.45 | — | — | — | |
EV/Sales |
2.27 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(0.81) | — | — | — | |
EV/FCF |
(0.79) | — | — | — | |
Quick Ratio |
0.00 | 5.66 | 0.00 | 4.74 | |
Current Ratio |
0.00 | 5.85 | 0.00 | 5.06 | |
Net Debt/EBITDA |
(3.50) | 0.00 | 0.00 | 1.88 | |
Debt/Assets |
0.00% | 25.15% | 0.00% | 34.85% | |
Debt/Equity |
0.00 | 0.42 | 0.00 | 0.71 | |
Asset Turnover |
0.50 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.00 | 2.22 | |
Capex/Depreciation |
— | — | — | 0.00 | |
Interest Coverage |
2.22 | — | (11.50) | (16.44) | |
Research and Development Expense of Revenue |
41.27% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.38% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | — | 0.00% | |
Graham Net Nets |
(0.11) | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(55.08%) | — | — | — | |
Free Cash Flow Yield |
(127.97%) | — | — | — | |
Revenue per Share |
1.18 | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | — | 0.00 | (1.11) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | — | 0.00 | (1.11) | |
Cash per Share |
1.66 | 0.00 | 2.21 | 1.88 | |
Shareholders Equity per Share |
2.61 | 0.00 | 1.58 | 1.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.61 | 0.00 | 1.58 | 1.28 | |
Free Cash Flow |
— | — | — | (8.26) | |
Working Capital |
10.57 | 20.64 | 18.44 | 12.73 | |
Net Current Asset Value |
(2.57) | 13.53 | 8.01 | 6.01 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.00 | — | — | — | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
— | 0.84 | — | 0.81 | |
Average Payables |
— | 2.44 | — | 2.08 | |
Average Assets |
21.31 | 21.82 | 18.06 | 20.91 | |
Average Common Equity |
8.34 | 7.69 | 11.76 | 7.88 |
Columns are period end dates